

22



REUNIÓN ANUAL

Sociedad Española de
Investigación sobre Cannabinoides

PAMPLONA

24 - 26 de Noviembre 2022

Patrocina:



Cima
Universidad
de Navarra



**22ª Reunión Anual de la
Sociedad Española de Investigación
sobre Cannabinoides**



Salón Actos Edificio Biblioteca de Ciencias
Universidad de Navarra

**Pamplona
24-26 noviembre, 2022**

Portada: Araceli Bergadá-Martínez

COMITÉ ORGANIZADOR

Marisol Aymerich (Universidad de Navarra-CIMA)

JUNTA DIRECTIVA

Presidente: Pedro Grandes Moreno (Universidad del País Vasco UPV/EHU, Leioa)

Vicepresidenta: Cristina Sánchez García (Universidad Complutense de Madrid)

Tesorera: Nadine Jagerovic (Instituto de Química Médica-CSIC)

Vocales: M^a Ruth Pazos Rodríguez (Hospital Universitario Fundación Alcorcón, Madrid)

Andrés Ozaita Mintegui (Universidad Pompeu Fabra, Barcelona)

Julián Romero Paredes (Universidad Francisco de Vitoria, Madrid)

Juan Suárez Pérez (IBIMA-Universidad de Málaga)

Carmen Rodríguez Cueto (Universidad Complutense de Madrid)

Secretaria: Nagore Puente Bustinza (Universidad del País Vasco UPV/EHU, Leioa)

Sociedad Española de Investigación sobre Cannabinoides

Departamento de Bioquímica y Biología Molecular

Facultad de Medicina

Universidad Complutense de Madrid

28040 Madrid (España)

PATROCINADORES ESTRATÉGICOS

FUNDACIÓN CANNA
PHYTOPLANT RESEARCH



PATROCINADORES

VIVACELL BIOTECHNOLOGY ESPAÑA
LINNEO HEALTH
IUIN
KHIRON LIFE SCIENCES
OBSERVATORIO ESPAÑOL DEL CANNABIS MEDICINAL (OECM)
CIMA UNIVERSIDAD DE NAVARRA



PROGRAMA CIENTÍFICO

Jueves, 24 de Noviembre

- 11:00-12:30** **Registro, entrega de documentación**
- 12:30-13:00** **Inauguración**
- Pedro Grandes Moreno (Presidente de la SEIC).
- Luis Montuenga (Decano Facultad de Ciencias, Universidad Navarra).
- Marisol Aymerich (Comité Organizador).
- 13:00-14:00** **Conferencia inaugural: *Brain aging and neurodegeneration: the challenge to develop cannabinoid-based neuroprotective therapies.***
Javier Fernández-Ruiz (Catedrático del Departamento de Bioquímica y Biología Molecular de la Facultad de Medicina de la Universidad Complutense de Madrid).

Presentado por Marisol Aymerich
- 14:00** **Comida**
- 15:30-16:30** **1ª Sesión de comunicaciones orales: Señalización del sistema endocannabinoide.**

Moderada por Cristina Miralpeix
- 15:30-15:45 O1.1
ANALYSIS OF ASTROGLIAL ENDOCANNABINOID PRODUCTION AND RELEASE.
Eraso-Pichot A., Olivera-Pinto A., Dalla-Tor T., Kedziora M., Fernández-Moncada I., Serrat R., Marsicano G.
- 15:45-16:00 O1.2
UBIQUITINATION OF CANNABINOID CB₁ RECEPTOR.
Álvaro-Blázquez A., Costas-Insua C., Hermoso-López A., Montero-Fernández C., Rodríguez-Crespo I., Guzmán M.
- 16:00-16:15 O1.3
CELLULAR SPECIFICITY AND SEXUAL DIMORPHISM OF HIPPOCAMPAL CB₁ RECEPTORS ON BEHAVIORAL PROCESSES.
Egaña-Huguet J., Sangroniz-Beltran L., Aranguren-Alberdi A., Reyes P., Bonilla-Del Río I., Puente N., Grandes P., Soria-Gómez E.

- 16:15-16:30 O1.4
EMBRYONIC CANNABINOID CB1 RECEPTOR KNOCKDOWN ALTERS THE NEUROGENIC GENE EXPRESSION PROGRAM AND FUNCTIONAL MATURATION OF PIRAMIDAL NEURONS.
Simón Sánchez S., García Rincón D., den Boon F., Skrempou G., Paraíso Luna J., Guzmán M., Chameau P., Galve Roperh I.
- 16:30-17:30 Café y 1ª sesión de paneles**
- 17:30-19:00 2ª Sesión de comunicaciones orales: Cannabinoides y neuroprotección en las enfermedades neurodegenerativas.**
- Moderada por Eva de Lago
- 17:30-17:45 O2.1
CANNABINOID CB₂ RECEPTOR MODULATION OF MICROGLIA FUNCTION IN A MOUSE MODEL OF ALZHEIMER DISEASE.
Ruiz de Martín Esteban S., Arnanz MA., Martínez-Relimpio AM., Mostany R., Hillard CJ., Grande T., Romero J.
- 17:45-18:00 O2.2
THE INHIBITION OF OX₁ RECEPTOR POTENTIATES THE CB₂R NEUROPROTECTIVE FUNCTION IN THE ALZHEIMER DISEASE.
Rebassa JB., Raich I., Lillo J., Cordomi A., Ribas-Santisteban R., Lillo A., Reyes-Resina I., Franco R., Navarro G.
- 18:00-18:15 O2.3
RELEVANCE OF NEURAL AND SKELETAL MUSCLE COMPARTMENTS FOR THE BENEFICIAL EFFECTS OF CB₂ RECEPTOR ACTIVATION IN EXPERIMENTAL ALS.
Gómez-Almería M., Gonzalo-Consuegra C., Rodríguez-Cueto C., Grether U., Fernández-Ruiz J., de Lago E.
- 18:15-18:30 O2.4
DEREGULATION ENDOCANNABINOID-MEDIATED NEURON-ASTROCYTE COMMUNICATION IN MULTIPLE SCLEROSIS.
Baraibar AM., Colomer T., Bernal-Chico A., Moreno-García A., Utrilla C., Serrat R., Marsicano G., Mato S.
- 18:30-18:45 O2.5
OLIGODENDROCYTE CB₁ RECEPTORS: MODULATION OF ENERGY METABOLISM AND ROLE DURING AUTOIMMUNE DEMYELINATION.
Sánchez-Martin E., Bernal-chico A., Aguado T., Ruiz A., Sánchez-Gómez MV., Guzmán M., Galve-Roperh I., Palazuelos J., Mato S.

18:45-19:00 O2.6
INVESTIGATION OF A CANNABIGEROL AMINOQUINONE DERIVATIVE AS A DISEASE-MODIFYING THERAPY IN AAV9-(A53T) α -SYNUCLEIN-LESIONED MICE, AN EXPERIMENTAL MODEL OF PARKINSON'S DISEASE.
Burgaz S., Rodríguez-Carreiro S., Navarro E., Navarrete C., Muñoz E., Fernández-Ruiz J.

Viernes, 25 de Noviembre

10:00-11:00 3ª Sesión de comunicaciones orales: Efectos de los Cannabinoides en la cognición.

Moderada por Edgar Soria

10:00-10:15 O3.1
SUB-CHRONIC PERIPHERAL CANNABINOID TYPE-1 RECEPTOR BLOCKADE ENHANCES COGNITIVE PERFORMANCE IN MICE.
Bergadá-Martínez A., Martínez-Torres S., de los Reyes-Ramírez L., Maldonado R., Ozaita A.

10:15-10:30 O3.2
RECOGNITION MEMORY IMPROVEMENT FOLLOWING WIN 55,212-2 ADMINISTRATION IN SURGICAL AND PHARMACOLOGICAL RAT MODELS OF CHOLINERGIC IMPAIRMENT.
Bengoetxea de Tena I., Moreno-Rodríguez M., Pereira-Castelo G., Martínez-Gardeazabal J., Manuel I., Rodríguez-Puertas R.

10:30-10:45 O3.3
A LOW REPEATED DOSE OF Δ^9 -Tetrahydrocannabinol affects memory performance through serotonergic signalling in mice
Galera-López L., Salgado-Mendialdúa V., Manzanares-Sierra I., Bergadá-Martínez A., Moreno E., Casado V., Hoffman A., Lupica C., Maldonado R., Ozaita A.

10:45-11:00 O3.4
SYNAPTONEUROSOMAL TRANSCRIPTOMIC ANALYSIS IN A FRAGILE X SYNDROME MOUSE MODEL REVEALS SPECIFIC ALTERATIONS SENSITIVE TO CB1 RECEPTOR TARGETING.
De los Reyes-Ramírez L., Bergadá-Martínez A., Reixachs-Solé M., Martínez-Torres S., Navarro-Romero A., Maldonado R., Eyras E., Ozaita A.

- 11:00-12:00** **Café y 2ª sesión de paneles**
- 12:00-13:00** **4ª Sesión de comunicaciones orales: Cannabinoides y neuroprotección en la hipoxia e isquemia.**
- Moderada por Teresa Grande
- 12:00-12:15 O4.1
REGULATION OF EXPRESSION OF CANNABINOID CB₂ AND SEROTONIN 5HT_{1A} RECEPTOR COMPLEXES BY CANNABINOIDS IN ANIMAL MODELS OF HYPOXIA AND IN OXYGEN/GLUCOSE-DEPRIVED NEURONS.
Lillo J., Raich I., Silva L., Zafra DA., Lillo A., Ferreiro-Vera C., Sánchez de Medina V., Martínez-Orgado J., Franco R, Navarro G.
- 12:15-12:30 O4.2
THE SYNTHETIC CANNABINOID URB477 IS NEUROPROTECTIVE AFTER INFECTION-SENSITIZED NEONATAL HYPOXIC-ISCHEMIC BRAIN INJURY.
Chillida M., Carloni S., Álvarez A., Beldarrain G., Alart JA., Álvarez FJ., Hilario E., Balduini W., Alonso-Alconada D.
- 12:30-12:45 O4.3
VCE-004.8 LEADS TO LONG-TERM NEUROPROTECTIVE EFFECTS WITH 12 H-LONG THERAPEUTIC WINDOW IN A NEWBORN RAT MODEL OF ARTERIAL ISCHEMIC STROKE.
Martínez M., Villa M., Silva L., De Hoz-Rivera M., Romero A., Godoy-Corchuelo JM., Hernández A., Muñoz E., Martínez-Orgado J.
- 12:45-13:00 O4.4
NEUROPROTECTIVE EFFECTS OF CBD IN A MODEL OF INFLAMATION-AUGMENTED HYPOXIC-ISCHEMIC BRAIN DAMAGE IN NEWBORN RATS.
Silva L., Villa M., Martínez M., Romero A., Rivera MH., Hernández A., Martínez-Orgado J.
- 13:00-14:00** **Hot Topic: Hacia una regulación del uso medicinal del Cannabis en España.**
Manuel Guzmán (Catedrático de Bioquímica y Biología Molecular en la Universidad Complutense de Madrid).

Presentado por Pedro Grandes.
- 14:00** **Comida**
- 15:30-16:30** **5ª Sesión de comunicaciones orales: Cannabinoides y cáncer.**
- Moderada por Gemma Navarro

15:30-15:45	O5.1 CANNABINOID-BASED STRATEGY TO INDUCE CANCER STEM CELL DIFFERENTIATION. <u>Martínez-Illescas N.</u> , Salazar-Roa M.
15:45-16:00	O5.2 THE ENDOCANNABINOID SYSTEM IN THE BREAST TUMOR MICROENVIRONMENT: ROLE IN TUMOR PROGRESSION AND RESPONSE TO IMMUNOTHERAPY. <u>Rubert M.</u> , Seijo-Vila M., Tundidor I., Sánchez C., Pérez-Gómez E., Blasco-Benito S.
16:00-16:15	O5.3 THE COMBINED ADMINISTRATION OF CANNABINOIDS AND INHIBITORS OF THE MDK/ALK AXIS AS A POTENTIAL THERAPEUTIC STRATEGY TO TARGET THE POPULATION OF GLIOMA INITIATING CELLS. <u>Tovar-Ambel E.</u> , López-Valero I., Sanz-Gálvez A., González Martínez J., Dávila D., Salvador-Tormo N., Kusaczuk M., Sánchez P., Sepúlveda JM., Lorente M., Velasco G.
16:15-16:30	O5.4 EFFECTS OF CHEMOTHERAPY DRUGS ON THE ENDOCANNABINOID SYSTEM OF RAT GASROINTESTINAL TISSUES. <u>López-Tofiño Y.</u> , Bagüés A., Vera G., Abalo R., Llorente-Berzal A.
16:30-17:30	Café, 3ª sesión de paneles
17:30-19:00	Asamblea Ordinaria de socios/as de la SEIC
19:00-19:15	Asamblea Extraordinaria de socios/as de la SEIC
21:00	Cena Congreso

- 10:00-10:45** **6ª Sesión de comunicaciones orales: Efectos del consumo de Cannabinoides**
- Moderada por Susana Mato
- 10:00-10:15 O6.1
ADOLESCENT EXPOSURE TO THE SPICE/K2 CANNABINOID JWH-018 IMPAIRS SENSORIMOTOR GATING AND ALTERS CORTICAL PERINEURONAL NETS IN A SEX-DEPENDENT MANNER.
Izquierdo-Luengo C., Ten-Blanco M., Ponce-Renilla M., Pereda-Pérez I., Berrendero F.
- 10:15-10:30 O6.2
THERAPEUTIC USE OF CANNABIS: ENCAPSULATION OF BIOACTIVE COMPOUNDS AND STUDY OF THE ENDOCANNABINOID SYSTEM
Villate A., San Nicolas M., Barreto PG., Olivares M., Etxebarria N., Aizpurua-Olaizola O., Usobiaga A., Unzueta-Larrinaga P., Barrena-Barbadillo R., Callado LF., Urigüen L.
- 10:30-10:45 O6.3
TECHNOLOGY DEVELOPMENT FOR QUALITY MEDICAL CANNABIS PRODUCTION IN TROPICAL CLIMATES
San Nicolas M., Villate A., Olivares M., Etxebarria N., Aizpurua-Olaizola O., Usobiaga A.
- 10:45-11:00** **Premio Fundación CANNA a la mejor publicación predoctoral 2022**
CANNABINOID CB₁ RECEPTOR GENE INACTIVATION IN OLIGODENDROCYTE PRECURSORS DISRUPTS OLIGODENDROGENESIS AND MYELINATION IN MICE.
Sánchez-de la Torre A.#, Aguado T.#, Huerga-Gómez A., Santamaría S., Gentile A., Chara JC., Matute C., Monory K., Mato S., Guzmán M., Lutz B., Galve-Roperh I., Palazuelos J.
- Presentado por Juan Suárez
- 11:00-11:15** **Premio Fundación CANNA a la mejor publicación postdoctoral 2022**
N-METHYL-D-ASPARTATE (NMDA) AND CANNABINOID CB₂ RECEPTORS FORM FUNCTIONAL COMPLEXES IN NEURAL CELLS. INSIGHTS INTO THE THERAPEUTIC POTENTIAL OF NMDA RECEPTORS IN NEURONS AND MICROGLIA.
Rivas-Santisteban R., Lillo A., Lillo J., Del-Ser A., Saura C., Franco R.*, Navarro G.*
- Presentado por Nadine Jagerovic

11:15-12:00

Café

12:00-13:00

Entrega de premios y clausura

PRIMERA SESIÓN DE PANELES

P1.1

ENDOCANNABINOID SYSTEM IN MÜLLER GLIAL CELLS.

Beriain S., Eraso-Pichot A., Vecino E., Marsicano G.

P1.2

LONG-TERM EFFECTS OF A TEMPORAL LOBE EPILEPSY MODEL ON THE MOUSE BRAIN: GLIAL CELLS AND CANNABINOID CB₁ RECEPTORS.

Ocerin G., Anaut-Lusar I., Mimenza A., Lekunberri L., Serrano M., Soria-Gómez E., Gerrikagoitia I., Rico-Barrio I., Puente N., Egaña-Huguet J., Elezgarai I., Grandes P.

P1.3

CB₁ RECEPTORS IN POMC NEURONS COORDINATE FEEDING AND FEAR BEHAVIOR.

Miralpeix C., Eraso-Pichot A., Skupio U., Jouque V., Quarta C., Marsicano G., Cota D.

P1.4

GHS-R1A-CB₁R COMPLEXES ARE UPREGULATED IN THE STRIATUM FROM OFFSPRING OF OBESITY MICE MODEL.

Lillo A., Lillo J., Raich I., Miralpeix C., Casals N., Franco R., Navarro G.

P1.5

MOLBOOLEAN: A NEW IN SITU APPROACH TO DETECT THE PERCENTAGE OF RECEPTORS FORMING HETEROMERS.

Reyes-Resina I., Rivas-Santisteban R., Fernández L., Navarro G., Franco R.

P1.6

TOWARDS A NEUROPROTECTIVE THERAPY BASED ON ACTIVATING CB₁ RECEPTORS IN TDP-43 DEPENDENT FRONTOTEMPORAL DEMENTIA.

Gonzalo-Consuegra C., Martín-Baquero R., Rodríguez-Cueto C., Fernández-Ruiz J., de Lago E.

P1.7

ELUCIDATING THE EFFECTS OF CHRONIC CANNABINOID TREATMENT IN A MOUSE MODEL OF ALZHEIMER'S DISEASE.

Vidal-Palencia L., Ramon-Duaso C., González-Parra JA., Busquets-García A.

P1.8

INVESTIGATION OF THE ENDOCANNABINOID SYSTEM IN A RAT MODEL OF NEUROPATHIC PAIN INDUCED BY REPEATED ADMINISTRATION OF VINCRISTINE.

López-Tofiño Y., Bagües A., Lynch K., Molony K., Boullón L., Vera G., Abalo R., Llorente-Berzal Á.

P1.9

MODULATION OF THE INFLAMMATORY REACTION THROUGH CB₂ RECEPTOR IS NEUROPROTECTIVE IN THE CHRONIC MPTP MOUSE MODEL.

Ayerra L., Abellanas MA., Basurco L., Zamarbide M., Luquin E., de Martín Esteban S., Martí MJ., Collantes M., Peñuelas I., Mengual E., Hillard CJ., Hervás-Stubbs S., Romero J., Aymerich MS

P2.1

MITOCHONDRIA-ENDOPLASMIC RETICULUM CONTACTS IN THE HIPPOCAMPUS LOCALIZE CANNABINOID CB₁ RECEPTORS.

Bonilla-Del Río I., Terradillos I., Gómez-Urquijo S., Puente N., Egaña-Huguet J., Reguero L., Rico-Barrio I., Soria-Gómez E., Ramos A., Gerrikagoitia I., Serrat R., Pouvreau S., Marsicano G., Grandes P.

P2.2

A₁-CB₁ HETEROMER COMPLEX AS A NEW THERAPEUTICAL TARGET FOR MULTIPLE SCLEROSIS.

Pérez-Olives C., Lillo A., Raïch I., Rivas-Santisteban R., Reyes-Resina I., Franco R., Navarro G.

P2.3

CANNABIDIOL IMPROVES MITOCHONDRIAL DISEASE PHENOTYPE IN A PPAR γ -DEPENDENT MANNER.

Puighermanal E., Menardy F., Gella A., van der Walt G., de Donato MH., Sanz E., Quintana A.

P2.4

AT₂-CB₁ AS TARGET TO COMBAT PARKINSON'S DISEASE. EXPRESSION AND SIGNAL FINGERPRINT OF AT₂-CB₁ RECEPTOR HETEROMERS IN STRIATAL NEURONS.

Rivas-Santisteban R., Lillo J., Raïch I., Lillo A., Navarro G., Franco R.

P2.5

PRENATAL ETHANOL CONSUMPTION INDUCES SEX-SPECIFIC CHANGES IN HIPPOCAMPAL ENDOCANNABINOID SIGNALING IN ADULT OFFSPRING OF 3XTG ALZHEIMER'S MOUSE MODEL.

Pacheco B., Ben Rabaa M., Tovar R., Sánchez L., Melgar S., Medina D., Rodríguez de Fonseca F., Suárez J., Rivera P.

P2.6

ASTROCYTE CALCIUM DYNAMICS IN MULTIPLE SCLEROSIS: DEFICIENT CONTROL BY CB₁ RECEPTOR.

Colomer-Mollá T., Sánchez-Martín E., Utrilla C., Moreno-García A., Bernal-Chico A., Ruiz A., Serrat R., Marsicano G., Mato S.

P2.7

EVALUATION OF THE ROLE OF MICROGLIA IN 5XFAD FAAH LACKING MICE: A MOLECULAR APPROACH.

Arnanz MA., Ruiz de Martín S., Grande MT., Ruiz-Pérez G., Cravatt BF., Romero J., Martínez Relimpio AM.

P2.8

CHANGES IN THE ENDOCANNABINOID SYSTEM AFTER INTRAVENTRICULAR HEMORRHAGE IN IMMATURE RAT BRAIN.

Romero A., de Hoz-Rivera M., Silva L., Villa M., Martínez M., Hernández A., Posada-Ayala M., Romero J., Martínez-Orgado J.

P2.9

ORALLY ACTIVE PEPTIDE VECTOR ALLOWS USING CANNABIS TO FIGHT PAIN WHILE AVOIDING SIDE EFFECTS.

Moreno E., Gallo M., Defaus S., Oretga-Alvaro A., Gonzalez A., Robledo P., Cavaco M., Neves V., Castanho MARB., Pardo L., Maldonado R., Andreu D., Casadó V.

TERCERA SESIÓN DE PANELES

P3.1

CB1R AS A POTENTIAL THERAPEUTIC TARGET IN CRBN DEFICIENCY-ASSOCIATED MENTAL RETARDATION.

Hermoso-López A., Costas-Insua C., Moreno E., Álvaro Blázquez A., Martín-Gutiérrez D., Maroto-Martínez IB., Montero-Fernández C., Díez-Alarcia R., Urigüen L., Casadó V., Rodríguez-Crespo I., Guzmán M.

P3.2

CB₂ RECEPTOR ANTAGONISM ABOLISHES CBD NEUROPROTECTIVE EFFECTS IN A RAT MODEL OF INTRAVENTRICULAR HEMORRHAGE IN PRETERM NEWBORN.

De Hoz-Rivera M., Del Pozo A., Romero A., Silva L., Martínez-Vega M., Villa M., Hernández A., Martínez-Orgado J.

P3.3

FUNCTIONAL SELECTIVITY OF THC, WIN55, 212-2, HU-210 AND CBD THROUGH CANNABINOID RECEPTORS IN POSTMORTEM HUMAN BRAIN CORTEX.

Díez-Alarcia R., Bedia I., Callado LF., Urigüen L.

P3.4

EFFECTS OF CBD ON BRAIN ENDOCANNABINOID CONCENTRATION TEMPORAL PROFILE AFTER HYPOXIA-ISCHEMIA IN NEWBORN PIGS.

Hernández A., Martínez M., Silva L., Rivera MH., Romero A., Vargas C., Gutiérrez-Rodríguez A., Hillard C., Martínez-Orgado J

P3.5

PLASMA ENDOCANNABINOIDS AS POTENTIAL BIOMARKERS OF TYPE 2 DIABETES MELLITUS IN ELDERLY PATIENTS WITH MILD COGNITIVE IMPAIRMENT.

López-Gambero AJ., Reyes JA., Fernández-Arjona MM., Rubio L., Rivera P., Serrano-Castro PJ., Rodríguez de Fonseca F., Suárez J.

P3.6

CANNABIDIOL INDIRECTLY REDUCES THE FUNCTIONALITY OF ADENOSINE A2A RECEPTORS.

Sánchez-Fernández N., Gómez-Acero L., Sarasola LI., Argerich J., Ciruela F., Fernández-Dueñas V., Aso E.

P3.7

EFFECT OF EXTRACTS FROM VARIETIES OF CANNABIS SATIVA L ON THE GI-MEDIATED SIGNALING OF THE CB₂ CANNABINOID RECEPTOR.

Franco R., Ferreiro Vera C., García Valverde MT., Sánchez de Medina V., Navarro G.

P3.8

NEUROBIOLOGICAL MECHANISMS UNDERLYING VULNERABILITY AND RESILIENCE TO CANNABIS ADDICTION.

Martin-Garcia E. Cajiao M., Casado-Anguera V., García-Blanco A., Maldonado R.

P3.9

ORAL BIOAVAILABILITY AND INTRAVENOUS PHARMACOKINETICS OF CANNABIDIOL IN HORSES WITH MICELLAR AND OIL FORMULATIONS.

Sánchez de Medina A., Serrano-Rodríguez JM., Díez de Castro E., García-Valverde MT., Saitua A., Becero M., Muñoz A., Ferreiro-Vera C., Sánchez de Medina V.

P3.10

CONTROLLED INHALATION OF HIGH-THC DRIED FLOWER CANNABIS IMPROVES QUALITY OF LIFE AND SYMPTOMS IN BRITISH PATIENTS WITH ANXIETY AND CHRONIC PAIN.

Moreno-Sanz G., Madiedo Á., Lynskey M., Brown MRD.

